Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-B-Lactamase-Producing Escherichia coli by Rodríguez-Baño, Jesús et al.
JOURNAL OF CLINICAL MICROBIOLOGY, May 2010, p. 1726–1731 Vol. 48, No. 5
0095-1137/10/$12.00 doi:10.1128/JCM.02353-09
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Risk Factors and Prognosis of Nosocomial Bloodstream Infections
Caused by Extended-Spectrum--Lactamase-Producing
Escherichia coli
Jesu´s Rodríguez-Ban˜o,1,2* Encarnacio´n Pico´n,3 Paloma Gijo´n,4 Jose´ Ramo´n Herna´ndez,3
Jose M. Cisneros,5 Carmen Pen˜a,6 Manuel Almela,7 Benito Almirante,8 Fabio Grill,9†
Javier Colomina,10 Sonia Molinos,11 Antonio Oliver,12 Carlos Ferna´ndez-Mazarrasa,13
Gemma Navarro,14 Ana Coloma,15 Lorena Lo´pez-Cerero,3,16 and Alvaro Pascual3,16
Seccio´n de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena, Seville,1 Departamento de Medicina, Universidad de
Seville, Seville,2 Servicio de Microbiología, Hospital Universitario Virgen Macarena, Seville,3 Servicio de Microbiología,
Hospital Universitario Gregorio Maran˜o´n, Madrid,4 Servicio de Enfermedades Infecciosas, Hospital Universitario Virgen del
Rocío, Seville,5 Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge, Barcelona,6 Servicio de
Enfermedades Infecciosas, Hospital Clinic, Barcelona,7 Servicio de Enfermedades Infecciosas, Hospital Universitario
Vall dHebro´n, Barcelona,8 Servicio de Enfermedades Infecciosas, Hospital Universitario Ramo´n y Cajal,
Madrid,9 Servicio de Microbiología, Hospital Universitario de la Ribera, Alcira,10 Servicio de Microbiología,
Hospital Universitario Germans Trias i Pujol, Badalona,11 Servicio de Microbiología, Hospital Universitario
Son Dureta, Palma de Mallorca,12 Servicio de Microbiología, Hospital Universitario Marque´s de
Valdecilla, Santander,13 Servicio de Epidemiología, Corporacio Sanitaria Parc Taulí, Sabadell,14
Unidad de Enfermedades Infecciosas, Hospital Santa Creu i San Pau, Barcelona,15
and Departamento de Microbiología, Universidad de Seville, Seville,16 Spain
Received 1 December 2009/Returned for modification 3 February 2010/Accepted 18 February 2010
Extended-spectrum--lactamase (ESBL)-producing Escherichia coli (ESBLEC) is an increasing cause of
community and nosocomial infections worldwide. However, there is scarce clinical information about nosoco-
mial bloodstream infections (BSIs) caused by these pathogens. We performed a study to investigate the risk
factors for and prognosis of nosocomial BSIs due to ESBLEC in 13 Spanish hospitals. Risk factors were
assessed by using a case-control-control study; 96 cases (2 to 16% of all nosocomial BSIs due to E. coli in the
participating centers) were included; the most frequent ESBL was CTX-M-14 (48% of the isolates). We found
CTX-M-15 in 10% of the isolates, which means that this enzyme is emerging as a cause of invasive infections
in Spain. By repetitive extragenic palindromic sequence-PCR, most isolates were found to be clonally unre-
lated. By multivariate analysis, the risk factors for nosocomial BSIs due to ESBLEC were found to be organ
transplant (odds ratio [OR]  4.8; 95% confidence interval [CI]  1.4 to 15.7), the previous use of oxyimino-
-lactams (OR  6.0; 95% CI  3.0 to 11.8), and unknown BSI source (protective; OR  0.4; 95% CI  0.2
to 0.9), and duration of hospital stay (OR  1.02; 95% CI  1.00 to 1.03). The variables independently
associated with mortality were a Pitt score of >1 (OR  3.9; 95% CI  1.2 to 12.9), a high-risk source (OR 
5.5; 95% CI  1.4 to 21.9), and resistance to more than three antibiotics, apart from penicillins and cepha-
losporins (OR 6.5; 95% CI 1.4 to 30.0). Inappropriate empirical therapy was not associated with mortality.
We conclude that ESBLEC is an important cause of nosocomial BSIs. The previous use of oxyimino--lactams
was the only modifiable risk factor found. Resistance to drugs other than penicillins and cephalosporins was
associated with increased mortality.
Gram-negative organisms are an important cause of noso-
comial bloodstream infections (BSIs) (33), particularly when
the source of the BSI is the urinary, respiratory, or gastroin-
testinal tract. Recently, the reemergence of Gram-negative
organisms as a cause of primary BSIs has also been reported
(1). In the United States, Escherichia coli is the fifth most
common cause of nosocomial BSIs and is the first most com-
mon cause among Gram-negative organisms, and BSIs caused
by E. coli are reported to be associated with a crude mortality
rate of 22% (34); in Spain, it is the second most common cause
of nosocomial BSIs (23).
In recent years, extended-spectrum ß-lactamases (ESBLs),
particularly those of the CTX-M family, have spread world-
wide among E. coli strains inside and outside hospitals (20, 26);
consequently, the prevalence of BSIs caused by ESBL-produc-
ing E. coli has significantly increased (24, 28). ESBLs confer
resistance to penicillins and cephalosporins and are frequently
associated with resistance to fluoroquinolones, aminoglyco-
sides, and trimethoprim-sulfamethoxazole (18); thus, ESBL-
producing microorganisms are frequently truly multidrug re-
sistant. Both antibiotic resistance and inappropriate empirical
therapy are independently associated with increased rates of
mortality among individuals with E. coli bacteremia (16, 19).
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ESBL production has been shown to be associated with de-
layed appropriate therapy and an increased risk of death (30).
Thus, identification of the risk factors for BSIs due to ESBL-
producing E. coli might help to identify patients who should
receive empirical coverage against these organisms and may
also be useful for control purposes.
The epidemiology of ESBL-producing E. coli within the
hospital environment shows some differences from that of
other multidrug-resistant organisms (29) but also from that of
other ESBL-producing organisms, such as Klebsiella pneu-
moniae. The latter frequently affects patients admitted to high-
risk areas (such as the intensive care unit [ICU] and the neo-
natal ICU), are predominantly clonally spread, and until
recently, typically produced ESBLs from the TEM and SHV
families (18), whereas nosocomial ESBL-producing E. coli
more frequently affects patients admitted to conventional hos-
pital units, are frequently clonally unrelated, and usually pro-
duce enzymes from the CTX-M family (25). While many stud-
ies have investigated the risk factors for nosocomial BSIs
caused by ESBL-producing K. pneumoniae or mixed infections
caused by members of the family Enterobacteriaceae (26), there
are scarce data concerning ESBL-producing E. coli. The ob-
jective of the study described here was to investigate the risk
factors, molecular epidemiology, and prognosis of nosocomial
BSIs due to ESBL-producing E. coli.
MATERIALS AND METHODS
Setting and design. Thirteen tertiary-care Spanish hospitals took part in the
study described here, which was conducted between October 2004 and Jan-
uary 2006. The risk factors for nosocomial BSIs due to ESBL-producing E.
coli were studied by using a case-control-control design (25). A case patient
was defined as any adult (14 years old) with a nosocomial BSI due to
ESBL-producing E. coli. Cases were recruited prospectively through the daily
review of blood culture results at the participating centers. For the study of
risk factors, two base populations were considered. The first was made up of
patients with nosocomial sepsis (“sepsis population”), who were identified as
all admitted patients from whom blood for culture was taken because of
suspected nosocomial sepsis (the blood cultures could be negative or positive
for any organism except ESBL-producing E. coli). The second constituted
patients with nosocomial BSIs due to non-ESBL-producing E. coli (the “E.
coli BSI population”). Two controls per case were chosen from both popu-
lations. Controls were matched to cases for hospital, ward type (medical,
surgical, or intensive care), and time period (1 month after the case). Control
patients were randomly selected from among the eligible patients by a com-
puterized method by using the blood culture register numbers in the micro-
biology laboratory of each participating hospital. The prognosis of BSI due to
ESBL-producing E. coli was studied in the case patients by prospectively
following the patients until discharge or in-hospital death.
We followed the recommendations of the STROBE statement for reporting
the results of observational studies (32). The study was approved by the local
ethics committees of the participating centers.
Definitions. A case of sepsis or BSI was defined as nosocomial when an
infection presented in patients who had been hospitalized for 48 h or more. The
following variables were recorded: demographics, comorbidities, the severity of
the underlying conditions according to the Charlson index (4), the surgical
procedures performed and the antimicrobial agents received during the present
admission, whether mechanical ventilation or a urinary or vascular catheter was
present, the endoscopic procedures performed in the previous 2 days, whether an
organ transplant had been performed during the previous year, the source of the
bacteremia (according to both clinical and microbiological criteria), whether
severe sepsis or septic shock was present at the time of presentation (2), and the
antimicrobial treatment and mortality at days 14 and 30. Empirical treatment was
considered appropriate when an antimicrobial regimen that included an active
antimicrobial (that is, one to which the organism causing the bacteremia was
susceptible in vitro) at the recommended doses was initiated in the first 24 h after
the blood sample for culture was drawn.
Microbiological studies. ESBL-producing isolates were sent to a reference
laboratory (Hospital Universitario Virgen Macarena, Seville, Spain), where
identification to the species level was confirmed by use of the API 20E system
(bioMe´rieux) and ESBL production was determined by broth microdilution,
according to the CLSI guidelines (8). Susceptibility to the antimicrobials
listed in Table 1 was evaluated by microdilution (8). A resistance score was
calculated as the number of antibiotic families (carbapenems, fluoroquino-
lones, -lactam–-lactam inhibitor combinations, trimethoprim-sulfamethox-
azole, aminoglycosides, and tigecycline), apart from penicillins and cephalo-
sporins, to which the isolate showed resistance, including those cases in which
resistance to only one antibiotic in the family occurred. ESBLs were charac-
terized by isoelectric focusing (Phastsystem; Pharmacia), PCR of the bla
genes (14), and sequencing. Strain relationships were studied by repetitive
extragenic palindromic sequence (REP)-PCR (31); isolates with similar REP-
PCR patterns were also studied by using pulsed-field gel electrophoresis
(PFGE) with XbaI endonuclease, according to a standardized XbaI PFGE
Pulsenet protocol (http://www.pulsenet-europe.org/); dendrograms were in-
ferred from the Dice similarity coefficient by use of a tolerance of 1%.
CTX-M-15-producing isolates were further studied in order to identify
O25b:H4 and sequence type 131 (ST131) clones; the phylogenetic group was
determined by multiplex PCR (5); O25b typing was performed by a previously
described PCR with primers rfbO25b.r and rfblbis.f (6); and analysis for allele
3 of pabB, which corresponds to ST131, was also performed by PCR with
specific primers (7). The genetic relatedness of the CTX-M-15-producing
isolates was studied by PFGE, as specified above.
Statistical analysis. For the investigation of risk factors, crude odds ratios
(ORs) and 95% confidence intervals (CIs) were calculated by conditional logistic
regression. Multivariate analysis was also performed by conditional logistic re-
gression. The variables introduced into the multivariate analysis included those
with a crude P value of 0.1, those that were biologically sound, and those found
in previous studies of ESBL-producing Enterobacteriaceae. Models including and
excluding the variable “hospital” were performed; however, since no significant
differences were shown, the models without that variable are reported here.
Interactions between paired variables were also analyzed. Variables were se-
lected by use of a stepwise backward process; previous hospital stay was kept in
the final model in order to provide an OR adjusted for the time at risk. Variables
associated with mortality were studied by calculating crude relative risks (RRs)
and 95% CIs; multivariate analysis was performed by logistic regression. Data
were analyzed by using the STATA (version 9.2) software package (StataCorp,
College Station, TX).
RESULTS
Ninety-six case patients with nosocomial BSIs due to ESBL-
producing E. coli were included. The median percentage of
nosocomial BSIs due to E. coli caused by ESBL-producing
isolates in participating hospitals was 8% (range, 2 to 16%).
The median incidence density was 0.20 cases per 10,000 pa-
tient-days (range, 0.11 to 1.70).
Overall, 78 isolates (81%) produced a CTX-M ESBL and 18
(19%) produced an SHV ESBL. The specific types of ESBLs
were CTX-M-14, 46 isolates (48% of the isolates) from 12
hospitals; CTX-M-9, 13 (14%) from 8 hospitals; CTX-M-15, 10
(10%) from 5 hospitals; CTX-M-32, 9 (9%) from 6 hospitals;
CTX-M-1, 2 (2%) from 1 hospital; SHV-12, 17 (18%) from 8
hospitals; and SHV-2a, 1 (1%) (2 isolates produced 2 CTX-M
enzymes). As regards the clonal relationship, only two isolates
producing CTX-M-14 and obtained from the same hospital
were clonally related by REP-PCR and PFGE. Seven of 10
CTX-M-15-producing isolates belonged to the B2 phylogroup
and were positive for the O25b O type and the allele-specific
pabB polymorphism by PCR assays. These seven isolates com-
prised six distinct PFGE types (60% similarity). Susceptibil-
ity testing results are shown in Table 1. The resistance scores
were 0 for 11 isolates (11%), 1 for 30 (31%), 2 for 25 (26%),
3 for 14 (15%), and 4 for 16 (17%).
The features of the case patients are shown in Table 2. Fifty
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patients (52%) were admitted to medical services, 32 (33%) to
surgical services, and 14 (15%) to an intensive care unit. The
control group for the sepsis population was made up of 190
patients (for 2 case patients, 1 control could not be found), and
that for the E. coli BSI population was made up of 186 patients
(for 6 case patients, 1 control could not be found). In Tables 2
to 4, control patients for the nosocomial sepsis population are
referred to as control group A, and control patients with nos-
ocomial bloodstream infections due to non-ESBL-producing
E. coli are referred to as control group B. The results of the
univariate analysis of risk factors for BSIs due to ESBL-pro-
ducing E. coli are shown in Tables 2 and 3. With regard to the
sepsis population, the following variables were introduced into
the multivariate analysis: age, gender, previous hospital stay,
TABLE 1. Susceptibilities to different antimicrobial agents of 96
extended-spectrum--lactamase-producing Escherichia coli
isolated from blood cultures
Antimicrobial agent No. (%)susceptible isolates
Cefotaxime .............................................................................. 2 (2)a
Ceftazidime .............................................................................58 (60)a
Cefepime .................................................................................32 (32)a
Amoxicillin-clavulanate .........................................................59 (62)
Piperacillin-tazobactam .........................................................86 (89)
Ticarcillin-clavulanate............................................................18 (19)
Imipenem ................................................................................96 (100)
Meropenem.............................................................................96 (100)
Ertapenem...............................................................................96 (100)
Ciprofloxacin...........................................................................28 (29)
Amikacin .................................................................................96 (100)
Gentamicin..............................................................................71 (74)
Tobramycin .............................................................................81 (84)
Tigecycline...............................................................................95 (99)
Trimethoprim-sulfamethoxazole ..........................................41 (43)
Fosfomycin ..............................................................................93 (97)
a Data were obtained by using the breakpoints for the Enterobacteriaceae (all
ESBL-producing isolates should be interpreted as resistant, according to CLSI
guidelines).
TABLE 2. Univariate analysis of risk factors for nosocomial bloodstream infection due to ESBL-producing Escherichia coli
compared with those for control patients from the nosocomial sepsis population and control patients with nosocomial
bloodstream infection due to non-ESBL-producing E. coli
Factor No. (%) of cases(n  96)
Analysis with control group A (n  190) Analysis with control group B (n  186)
No. (%)
of patients OR (95% CI) P
No. (%)
of patients OR (95% CI) P
Age  65 years 45 (47) 97 (51) 0.8 (0.5–1.3) 0.5 115 (62) 0.5 (0.3–0.8) 0.01
Female gender 42 (44) 73 (38) 1.2 (0.7–2.0) 0.3 76 (41) 1.1 (0.6–1.8) 0.6
Charlson index  2 40 (42) 64 (34) 1.4 (0.8–2.3) 0.1 71 (38) 1.1 (0.7–1.9) 0.5
Organ transplant 9 (9) 9 (5) 2.0 (0.7–5.4) 0.1 5 (3) 3.7 (1.2–11.5) 0.02
Diabetes mellitus 28 (29) 38 (20) 1.6 (0.9–5.4) 0.08 43 (23) 1.3 (0.7–2.3) 0.2
Chronic pulmonary disease 16 (17) 27 (14) 1.2 (0.6–2.3) 0.5 23 (12) 1.4 (0.7–2.8) 0.3
Heart failure 13 (14) 24 (13) 1.0 (0.5–2.2) 0.8 24 (23) 1.0 (0.5–2.1) 0.8
Neoplasia 31 (32) 61 (32) 1.0 (0.5–1.7) 0.9 77 (41) 0.6 (0.4–1.1) 0.1
Liver cirrhosis 8 (8) 11 (6) 1.4 (0.5–3.8) 0.4 11 (6) 1.4 (0.5–3.7) 0.4
Chronic renal insufficiency 18 (19) 28 (15) 1.3 (0.6–2.5) 0.3 23 (12) 1.6 (0.8–3.2) 0.1
Immunosuppressive drug treatment 20 (21) 34 (18) 1.2 (0.6–2.2) 0.5 33 17() 1.2 (0.6–2.2) 0.5
Obstructive urinary disease 16 (17) 18 (10) 1.9 (0.9–3.9) 0.07 24 (13) 1.3 (0.6–2.6) 0.3
Biliary disease 10 (10) 14 (7) 1.4 (0.9–3.9) 0.3 15 (13) 0.7 (0.3–1.6) 0.4
Neutropenia 6 (6) 9 (5) 1.3 (0.4–3.4) 0.5 15 (8) 0.7 (0.2–2.0) 0.5
Hemodialysis 4 (4) 5 (3) 1.3 (0.6–2.8) 0.4 1 (1) 8.0 (0.8–191.7) 0.04
Central venous catheter 45 (47) 88 (46) 1.0 (0.6–1.6) 0.9 77 (40) 1.3 (0.8–2.1) 0.2
Foley catheter 43 (45) 65 (34) 1.5 (0.9–2.5) 0.08 70 (38) 1.3 (0.8–2.2) 0.2
Mechanical ventilation 8 (8) 22 (12) 0.6 (0.2–1.6) 0.3 18 (10) 0.8 (0.3–2.0) 0.7
Surgery 32 (33) 62 (33) 1.0 (0.6–4.7) 0.9 48 (26) 1.4 (0.8–2.4) 0.1
Endoscopic procedure 9 (9) 10 (5) 1.8 (0.7–4.7) 0.1 13 (7) 1.3 (0.5–3.3) 0.4
Urological procedure 7 (7) 5 (3) 2.9 (0.8–9.4) 0.06 10 (5) 1.3 (0.5–3.7) 0.5
Previous antimicrobial use 69 (72) 92 (48) 2.7 (1.6–4.6) 0.001 96 (52) 2.3 (1.4–4.0) 0.001
Aminopenicillin use 13 (14) 31 (16) 0.8 (0.3–1.6) 0.5 37 (20) 0.6 (0.3–1.2) 0.1
Oxyimino--lactam use 35 (37) 28 (15) 3.3 (1.8–5.9) 0.001 17 (9) 5.7 (2.9–10.9) 0.001
Carbapenem use 8 (8) 16 (8) 0.9 (0.4–2.3) 0.9 8 (4) 2.0 (0.7–5.5) 0.1
Fluoroquinolone use 24 (25) 28 (15) 1.9 (1.0–3.5) 0.03 27 (15) 1.9 (1.0–3.6) 0.03
Previous hospital staya 24 (31) 18 (18) 0.05 15 (13) 0.001
a Data in this row have units of mean number of days (standard deviation).
TABLE 3. Source of nosocomial bloodstream infections caused by
ESBL-producing Escherichia coli compared with that in control
patients with nosocomial bloodstream infection due
to non-ESBL-producing E. coli
Source
No. (%) of patients
OR (95% CI) PCases
(n  96)
Control group
B (n  186)
Urinary tract infection 34 (35) 63 (34) 1.0 (0.6–1.8) 0.7
Intra-abdominal
infectiona
24 (25) 45 (24) 1.0 (0.7–1.9) 0.8
Respiratory tract
infectionb
6 (6) 7 (4) 1.7 (0.4–1.8) 0.3
Vascular catheter
infection
8 (8) 7 (4) 1.6 (0.9–2.6) 0.1
Other 5 (5) 9 (5) 1.0 (0.3–3.6) 0.8
Unknown 19 (20) 55 (30) 0.6 (0.3–1.1) 0.07
a Biliary tract infection in 12 case patients and 28 control patients.
b Pneumonia in four case patients and five control patients.
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Charlson index, diabetes mellitus, obstructive disease of the
urinary tract, the presence of a urinary catheter, the perfor-
mance of any other invasive procedure involving the urinary
tract, and previous antimicrobial use. With regard to the noso-
comial BSIs due to the E. coli population, the following vari-
ables were introduced into the multivariate analysis: age,
gender, previous hospital stay, Charlson index, organ trans-
plantation, the use of hemodialysis, the previous use of anti-
microbials, and an unknown source. The following variables
were independently associated with bacteremia due to ESBL-
producing E. coli in the sepsis population: diabetes mellitus
and the previous use of oxyimino--lactams. For the E. coli BSI
population, the independent risk factors were previous hospi-
tal stay, organ transplantation, the previous use of oxyimino-
-lactams, and an unknown source of BSI (protective) (Table
4). By considering the risk factors found with regard to the E.
coli BSI population (and using 20 days of a previous hospital
stay as the cutoff point), only 8 cases (8%) had no risk factors,
36 (38%) had one, 37 (38%) had two, and 15 (16%) had more
than two.
Among the patients with nosocomial BSIs due to ESBL-pro-
ducing E. coli, 27 (28%) presented with severe sepsis or septic
shock; 43 (45%) received inappropriate antimicrobial therapy.
The crude mortality rates were 25% (24 patients) at day 14 and
30% (29 patients) at day 30. Inappropriate empirical therapy was
not associated with a significantly increased risk of mortality by 14
days or 30 days. The results of the multivariate analysis of the
variables associated with mortality at 14 and 30 days are shown in
Table 5. We found no significant differences in epidemiology,
clinical features, or prognosis by type of ESBL produced (data not
shown).
DISCUSSION
Our study shows that ESBL-producing E. coli caused a sig-
nificant proportion of all nosocomial BSIs due to E. coli in the
participating hospitals, although there were significant differ-
ences in incidence. Whether this heterogeneity of incidence
relates to differences in antimicrobial consumption or to the
epidemiology of ESBL-producing E. coli in the area concerned
remains to be investigated. The features of ESBL-producing E.
coli isolated from patients with nosocomial BSIs resemble
those for ESBL-producing E. coli isolated from patients with
community-onset infections and colonization in Spain (21, 22,
27). In a study from Israel, patients colonized with ESBL-
producing enterobacteria were at an increased risk of devel-
oping BSIs during their hospital stays (3). We hypothesize that
many patients were probably colonized at admission and de-
veloped the infection in hospital. In fact, the molecular typing
results obtained by REP-PCR and PFGE argue strongly
against the frequent cross-transmission of ESBL-producing E.
coli isolates causing BSIs in the participating hospitals. Other
typing techniques, such as multilocus sequence typing, may
find that isolates with different PFGE types belong to the same
sequence typing group; however, although this technique is
very useful for the long-term delineation of clonal evolution, it
is not so for short-term epidemiological analysis (9). Whether
plasmid transmission is a relevant means of spread of ESBLs
among E. coli isolates in the hospital setting, as was demon-
strated with ESBL-producing K. pneumoniae, is a question that
not yet been thoroughly studied.
CTX-M-14 has been the predominant ESBL in community
isolates in Spain, being obtained from urinary tract infections
and fecal samples (21, 22). However, CTX-M-15, which is
associated with the global spread of clonal group ST131 (15)
and the predominant ESBL in many countries worldwide, has
recently emerged in Spain and has been found to spread in the
community, nursing homes, and hospitals in Madrid (17). In
our study, 10% of cases produced CTX-M-15, and most of
them belonged to the ST131 clonal group; these cases were
detected in five hospitals from Madrid, Barcelona, and Mal-
lorca, suggesting local differences in the spread of these iso-
lates.
The best control group for use in the investigation of risk
factors depends on the specific research question (12). We
used two control groups: one to investigate the risk factors for
ESBL-producing E. coli in patients with nosocomial sepsis and
one to investigate nosocomial BSIs due to E. coli. The risk
factors found in a comparison with controls from the nosoco-
mial sepsis population might be nonspecifically associated with
BSIs due to E. coli; this could be the case for diabetes mellitus.
The fact that previous oxyimino--lactam use was associated
with ESBL-producing E. coli in comparisons with both the
nosocomial sepsis and the E. coli nosocomial BSI populations
indicates that this is a true risk factor, although the OR found
with the second population is probably overestimated (12).
Finally, although only 9% of the case patients had undergone
an organ transplant, we found that organ transplantation was
independently associated with ESBL-producing E. coli in pa-
tients with nosocomial BSIs due to E. coli. Studies described in
recent reports found that ESBL-producing E. coli frequently
causes infections in transplant patients (10, 11, 13). We hy-
pothesize that an organ transplant may act as a surrogate
marker for other variables which may increase the probability
of colonization and invasive infection due to ESBL-producing
E. coli.
From a clinical point of view, one important aspect is the
fact that about half of the patients with BSIs due to ESBL-
producing E. coli received inappropriate empirical therapy,
although mortality was associated with the severity of the clin-
ical situation, the BSI source, and infections with highly resis-
tant isolates rather than inappropriate therapy. Since inappro-
priate therapy was an independent predictor of mortality in
TABLE 4. Multivariate analysis of risk factors for nosocomial
bloodstream infection due to ESBL-producing Escherichia coli
Control group and risk
factor

coefficient OR (95% CI) P
Control group A
Diabetes mellitus 0.5 1.6 (0.9–2.9) 0.09
Previous oxyimino--
lactam use
1.16 3.1 (1.7–5.7) 0.001
Hospital stay (per day) 0.007 1.00 (0.99–1.01) 0.1
Control group B
Transplant 1.57 4.8 (1.4–15.7) 0.009
Previous oxyimino--
lactam use
1.79 6.0 (3.0–11.8) 0.001
Unknown source 0.71 0.4 (0.2–0.9) 0.03
Hospital stay (per day) 0.02 1.02 (1.00–1.03) 0.01
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two recent large cohorts of patients with BSIs due to E. coli,
our study may have been underpowered to detect such an
association.
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TABLE 5. Univariate and multivariate analyses of risk factors for 14-day and 30-day mortality among patients with bloodstream infections
due to extended-spectrum -lactamase-producing Escherichia coli
Time of mortality
measure and risk factor
No. of patients who
died/total no. of
patients (%)
RR (95% CI) P for RR Adjusted OR (95% CI) P foradjusted OR
14-day mortality
Gender
Male 13/54 (24) 1.0 (0.5–2.1) 0.8
Female 11/42 (26)
Age (yr)
65 12/45 (27) 1.1 (0.5–2.2) 0.7
14–65 12/51 (24)
Charlson index
2 15/40 (38) 2.3 (1.1–4.7) 0.01
0-2 9/56 (16)
Pitt score
1 17/37 (46) 3.8 (1.7–8.4) 0.001 3.9 (1.2–12.9) 0.02
0–1 7/59 (12)
High-risk sourcea
Yes 19/48 (40) 3.8 (1.5–9.3) 0.001 5.5 (1.4–21.9) 0.01
No 5/48 (10)
Severe sepsis or
shock
Yes 15/27 (56) 4.2 (2.1–8.5) 0.001 4.6 (1.4–15.2) 0.01
No 9/69 (13)
Resistance score
3 8/16 (50) 2.5 (1.2–4.8) 0.02 6.5 (1.4–30.0) 0.01
0–3 16/80 (20)
Empirical treatment
Inappropriate 11/43 (26) 1.0 (0.5–2.0) 0.9
Appropriate 11/53 (25)
30-day mortality
Gender
Male 16/54 (30) 1.0 (0.05–1.9) 0.8
Female 13/42 (26)
Age (yr)
65 14/45 (31) 1.0 (0.5–1.9) 0.8
14-65 15/51 (29)
Charlson index
2 18/40 (45) 2.3 (1.2–4.3) 0.008 2.7 (0.8–9.0) 0.09
0-2 11/56 (20)
Pitt score
1 21/37 (57) 4.3 (2.0–9.0) 0.001 5.5 (1.9–21.3) 0.002
0–1 8/59 (14)
High-risk sourcea
Yes 23/48 (48) 3.8 (1.7–9.0) 0.001 5.8 (1.5–21.7) 0.008
No 6/48 (13)
Severe sepsis or
shock
Yes 17/27 (63) 3.7 (2.0–6.6) 0.001 3.5 (1.1–11.6) 0.03
No 12/69 (17)
Resistance score
3 8/16 (50) 1.9 (1.0–3.5) 0.07 4.9 (1.0–23.0) 0.04
0–3 21/80 (26)
Empirical treatment
Inappropriate 13/43 (30) 1.0 (0.5–1.8) 0.9
Appropriate 16/53 (30)
a High-risk source: intra-abdominal infection, respiratory tract infection, and unknown source.
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